Guangxi Medical University Cancer Hospital — Nanning, Guangxi

Public research footprint of Guangxi Medical University Cancer Hospital, compiled from the ClinicalTrials.gov public registry.

139

Registered studies

112

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer · Advanced Lung Cancer · Gastric Cancer · Advanced Solid Tumor

Recently updated registry entries

NCT07492641 — BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or… (Recruiting)
NCT05920356 — A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum… (Recruiting)
NCT04613596 — Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase… (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Guangxi Medical University Cancer Hospital?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 06, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.